Effects of teriparatide and alendronate on bone mineral density of osteoporotic rats

National Medical Journal of China

Volumn 85, Issue 5, 2005, Pages 335-338

  Li, Mei ^a   Jiao, Jie ^b   Meng, Xun Wu ^b   Xing, Xiao Ping ^b   Xia, Wei Bo ^b   Zhou, Xue Ying ^b   Liu, Huai Ching ^b   Jiang, Yan ^b   Wang, Ou ^b   Hu, Ying Ying ^b   Zhang, Zhan Wei ^b  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b NONE

Author keywords

Alendronate; Bone density; Osteoporosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALENDRONIC ACID; ALKALINE PHOSPHATASE; CALCIUM; CREATININE; DEOXYPYRIDINOLINE; PARATHYROID HORMONE[1-34]; PHOSPHATE;

ABSORPTIOMETRY; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CALCIUM BLOOD LEVEL; CHEMICAL ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; FEMALE; FEMUR; LUMBAR VERTEBRA; NEWBORN; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; PHOSPHATE BLOOD LEVEL; RANDOMIZATION; RAT; RAT STRAIN; SERUM; STATISTICAL SIGNIFICANCE; URINALYSIS;

ALENDRONATE; ANIMALS; BONE DENSITY; BONE REMODELING; DRUG THERAPY, COMBINATION; FEMALE; OSTEOPOROSIS; OVARIECTOMY; RANDOM ALLOCATION; RATS; RATS, WISTAR; TERIPARATIDE;

EID: 13844298828     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Brixen KT, Christensen B, Ejersted C, et al. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis. Basic Clin Pharmacol Toxicol, 2004, 94:260-270.
2. Li M, Meng XU, Xing XP, et al. The effects of human parathyroid hormone (hPTH1-34) different administration on SaoS -2 Cells. Acta Acad Med Sin, 2004,26:30-33.
3. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone ( 1-34 ) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med,2001,344: 1434-1441.
4. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet, 2002, 359:2018-2026.
5. Doggrell SA. Does the combination of alendronate and parathyroid hormone give a greater benefit than either agent alone in osteoporosis? Expert Opin Pharmacother, 2004, 5:955-958.
6. Sugiyama T, Tanaka H, Kawai S. Effects of parathyroid hormone and alendronate alone or in combination in osteoporosis. N Engl J Med, 2004, 350:189-192.
7. Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med, 2003, 349:1207-1215.
8. Finkelstein JS, Hayes A, Hunzelman, et al. Parathyroid hormone (1-34) alone was better than parathyroid hormone plus alendronate in men with osteoporosis. N Engl J Med, 2003, 349:1216-1226.
9. Khosla S. Parathyroid hormone plus alendronate - a combination that does not add up. N Engl J Med, 2003, 349:1277-1279.
10. Ma YL, Bryant HU, Zeng Q, et al. New bone formation with teriparatide [human parathyroid hormone-(1-34)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats. Endocrinology, 2003, 144:2008-2015.
11. Rittmaster RS, Bolognese M, Ettinger MP, et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab, 2000, 85;2129-2134.
12. Dempster DW. The impact of bone turnover and bone-active agents on bone quality: focus on the hip. Osteoporos Int, 2002, 13:349-352.
13. Meunier PJ. Anabolic agents for treating postmenopausal osteoporosis. Joint Bone Spine, 2001, 68:576-581.